Key Points
- COO Jian Xie sold 10,000 shares of Fulgent Genetics at an average price of $29.10 on Nov. 19 for $291,000, reducing his stake by 2.78% to 349,768 shares valued at about $10.18 million.
- FLGT shares rose 4.2% to $30.00 on the report, with a market cap near $927 million and a 52-week range of $14.57–$30.59.
- Fulgent beat estimates for the quarter with $0.14 EPS vs. a -$0.22 consensus and $84.07M revenue, issued FY2025 EPS guidance of 0.30, and currently carries a consensus analyst rating of "Hold" with an average target of $32.00.
Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) COO Jian Xie sold 10,000 shares of the stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $29.10, for a total value of $291,000.00. Following the transaction, the chief operating officer directly owned 349,768 shares in the company, valued at $10,178,248.80. The trade was a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Jian Xie also recently made the following trade(s):
- On Wednesday, September 3rd, Jian Xie sold 1,128 shares of Fulgent Genetics stock. The stock was sold at an average price of $22.03, for a total value of $24,849.84.
- On Wednesday, August 27th, Jian Xie sold 1,199 shares of Fulgent Genetics stock. The shares were sold at an average price of $21.48, for a total value of $25,754.52.
- On Monday, August 25th, Jian Xie sold 696 shares of Fulgent Genetics stock. The shares were sold at an average price of $21.50, for a total value of $14,964.00.
Fulgent Genetics Stock Up 4.2%
NASDAQ:FLGT traded up $1.22 on Friday, hitting $30.00. The stock had a trading volume of 321,112 shares, compared to its average volume of 330,612. The business's 50-day simple moving average is $24.04 and its two-hundred day simple moving average is $21.59. The stock has a market cap of $927.36 million, a price-to-earnings ratio of -18.07 and a beta of 0.92. Fulgent Genetics, Inc. has a 52-week low of $14.57 and a 52-week high of $30.59.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last issued its quarterly earnings data on Friday, November 7th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.36. The firm had revenue of $84.07 million for the quarter, compared to analysts' expectations of $81.43 million. Fulgent Genetics had a negative net margin of 16.83% and a negative return on equity of 2.26%. Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. As a group, equities research analysts anticipate that Fulgent Genetics, Inc. will post -0.85 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have recently weighed in on FLGT shares. Raymond James Financial reiterated an "outperform" rating and set a $36.00 price target on shares of Fulgent Genetics in a research note on Friday, November 14th. Wall Street Zen raised Fulgent Genetics from a "hold" rating to a "buy" rating in a report on Saturday, November 15th. Piper Sandler lifted their target price on Fulgent Genetics from $21.00 to $30.00 and gave the company a "neutral" rating in a research report on Tuesday, November 11th. UBS Group upgraded Fulgent Genetics from a "neutral" rating to a "buy" rating and upped their price target for the stock from $20.00 to $30.00 in a research report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fulgent Genetics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $32.00.
Read Our Latest Report on FLGT
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Signaturefd LLC boosted its holdings in Fulgent Genetics by 60.4% in the 2nd quarter. Signaturefd LLC now owns 1,914 shares of the company's stock worth $38,000 after buying an additional 721 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Fulgent Genetics in the second quarter valued at about $49,000. PNC Financial Services Group Inc. boosted its stake in shares of Fulgent Genetics by 122.8% in the first quarter. PNC Financial Services Group Inc. now owns 3,562 shares of the company's stock worth $60,000 after acquiring an additional 1,963 shares during the period. Quantbot Technologies LP bought a new position in shares of Fulgent Genetics in the third quarter worth about $61,000. Finally, State of Wyoming grew its position in shares of Fulgent Genetics by 111.1% during the first quarter. State of Wyoming now owns 6,564 shares of the company's stock worth $111,000 after purchasing an additional 3,455 shares in the last quarter. Hedge funds and other institutional investors own 48.06% of the company's stock.
Fulgent Genetics Company Profile
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
